EPO Patents = 1

Forward Citations = 45

Loading Chart...

2 inventors (with patents filed for the assignee):

Anatole A Klyosov (4 out of 28 patents)

David C Platt (4 out of 64 patents)

4 patents: Sort by Forward Citations

1. 7893252 - Selectively depolymerized galactomannan polysaccharide (2011-02-22),

2. 7012068 - Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer (2006-03-14),

3. 6645946 - Delivery of a therapeutic agent in a formulation for reduced toxicity (2003-11-11),

4. 6642205 - Methods and compositions for reducing side effects in chemotherapeutic treatments (2003-11-04),

Pro-pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat various types of cancer. Their lead product candidate, PRX302, is currently in clinical trials for the treatment of bladder cancer. With a strong focus on research and innovation, Pro-pharmaceuticals aims to improve the lives of cancer patients through the development of new and effective treatments.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

4 Patents

#65 in Newton, MA

#3,234 in Massachusetts

#59,078 in US

Newton, MA, United States of America

Pro-Pharmaceuticals, Inc.

Forward Citations = 45

2 inventors:

Anatole A Klyosov (4 out of 28 patents)

David C Platt (4 out of 64 patents)

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com